Inolimomab
Inolimomab
Inolimomab (pronounced as i-no-li-mo-mab) is a type of monoclonal antibody used in the treatment of certain medical conditions.
Etymology
The name 'Inolimomab' is derived from the following components: 'Ino' refers to the mouse origin of the antibody, 'li' signifies the targeted immune system, 'mo' indicates the monoclonal nature of the antibody, and 'mab' is the standard suffix for monoclonal antibodies.
Usage
Inolimomab is primarily used in the treatment of Graft-versus-host disease (GvHD), a condition that might occur after an allogeneic tissue transplant, which happens when a person receives bone marrow or stem cells from a donor.
Mechanism of Action
Inolimomab works by binding to the interleukin-2 receptor (IL-2R) on the surface of certain immune cells, known as T cells. By blocking IL-2R, Inolimomab inhibits the activation and proliferation of T cells, which are involved in the immune response that causes GvHD.
Related Terms
- Monoclonal Antibodies: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Graft-versus-host disease: A complication that can occur after a stem cell or bone marrow transplant.
- Allogeneic tissue transplant: A procedure in which a person receives bone marrow or stem cells from a genetically similar, but not identical, donor.
- Interleukin-2 receptor: A protein found on the surface of certain immune cells, to which interleukin-2 can bind.
External links
- Medical encyclopedia article on Inolimomab
- Wikipedia's article - Inolimomab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski